An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2018
At a glance
- Drugs AZD 9496 (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 20 Nov 2018 Planned number of patients changed from 48 to 54.
- 20 Nov 2018 Planned End Date changed from 8 Feb 2019 to 15 Feb 2019.
- 20 Nov 2018 Planned primary completion date changed from 8 Feb 2019 to 15 Feb 2019.